ZANTAC 300
LOE ApproachingNDAORALCAPSULE
Approved
Mar 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZANTAC 300 is an oral capsule histamine H2-receptor antagonist approved in 1994 for gastrointestinal acid-related disorders. The mechanism reduces gastric acid secretion by blocking H2 receptors on parietal cells. It is used for conditions such as peptic ulcer disease, gastroesophageal reflux disease (GERD), and acid indigestion.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), signaling transition from growth to maintenance and eventual post-LOE team restructuring.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Career roles on ZANTAC 300 are primarily focused on defending market share and managing the transition to generic competition rather than driving growth. This product offers stable but limited advancement opportunities, with emphasis on operational excellence and cost management in the LOE phase.
Brand ManagerSales Representative
Worked on ZANTAC 300 at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.